NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Forecasting Remove constraint Subjects: Forecasting Subjects United States Remove constraint Subjects: United States Copyright Public domain Remove constraint Copyright: Public domain Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

2. Questionable billing for compounded topical drugs in Medicare Part D

4. Possible higher spending paths for veterans' benefits

6. The aging services network: accomplishments and challenges in serving a growing elderly population

7. The budget and economic outlook: 2018 to 2028

8. Federal mandatory spending for means-tested programs, 2008 to 2028

9. How CBO adjusts for survey underreporting of transfer income in its distributional analyses

11. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

12. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

14. Health insurance coverage for people under age 65: definitions and estimates for 2015 to 2018

15. Federal mandatory spending for means-tested programs: 2009 to 2029

17. Projecting demand for the services of primary care doctors:

19. Trends in enrollment, offers, eligibility and take-up for employer-sponsored insurance: private sector, by state Medicaid expansion status, 2008-2015

20. Federal subsidies for health insurance coverage for people under age 65: 2017 to 2027

21. Preliminary analysis of legislation that would replace subsidies for health care with block grants

26. Rebalancing long-term care: the role of the Medicaid HCBS waiver program

28. Shaping Medicaid and SCHIP through waivers: the fundamentals

29. Physician workforce: locations and types of graduate training were largely unchanged, and federal efforts may not be sufficient to meet needs : report to Congressional requesters

30. Medicaid expansion: behavioral health treatment use in selected states in 2014 : report to Congressional requesters

31. Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

32. Drug control policy: information on status of federal efforts and key issues for preventing illicit drug use : testimony before the Committee on Oversight and Government Reform, House of Representatives

33. Personal firearms: programs that promote safe storage and research on their effectiveness : report to Congressional requesters

34. Low-wage workers: poverty and use of selected federal social safety net programs persist among working families : report to the ranking member, Subcommittee on Primary Health and Retirement Security, Committee on Health, Education, Labor, and Pensions, U.S. Senate

35. Federal employees health benefits program: enrollment remains concentrated despite more plan offerings, and effects of adding plan types are uncertain : report to the ranking member, Committee on Oversight and Government Reform, House of Representatives

36. Counternarcotics: overview of U.S. efforts in the Western Hemisphere : report to the ranking member, Committee on Foreign Affairs, House of Representatives

37. Child well-being: key considerations for policymakers including the need for a federal cross-agency priority goal : a report to Congress

38. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

39. Social Security disability: additional measures and evaluation needed to enhance accuracy and consistency of hearings decisions : report to the Chairman, Subcommittee on Social Security, Committee on Ways and Means, House of Representatives

40. FDA medical device reviews: evaluation is needed to assure requests for additional information follow a least burdensome approach : report to Congressional requestors

41. National security: long-range emerging threats facing the United States as identified by federal agencies : report to Congressional committees

42. Opioid use decreased in Medicare Part D, while medication-assisted treatment increased

44. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

47. Long-term projections of health care spending and the implications for the federal budget: presentation at the 15th annual meeting of the OECD’s working party of parliamentary budget officials and independent fiscal institutions